Cite
HARVARD Citation
Callis Duffin, K. et al. (n.d.). Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A). Journal of the European Academy of Dermatology and Venereology. pp. 107-113. [Online].